Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Loading ALIM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.15%72.471.2%$698.33m
CELGCelgene Corporation
0.71%117.391.3%$685.14m
AMGNAmgen Inc.
-0.15%145.071.0%$640.82m
BIIBBiogen Inc.
0.25%290.961.2%$543.42m
REGNRegeneron Pharmaceuticals, Inc.
-0.24%368.953.6%$400.43m
ALXNAlexion Pharmaceuticals, Inc.
-0.61%124.171.9%$372.24m
ILMNIllumina, Inc.
-1.19%126.403.0%$184.89m
VRTXVertex Pharmaceuticals Incorporated
3.40%78.122.9%$171.61m
INCYIncyte Corporation
2.34%107.212.4%$169.49m
TSROTESARO, Inc.
0.22%139.8717.1%$164.06m
IONSIonis Pharmaceuticals, Inc.
3.15%47.4510.0%$156.72m
EXELExelixis, Inc.
2.36%18.256.4%$128.45m
BLUEBluebird Bio, Inc.
9.43%78.9523.3%$121.32m
BMRNBioMarin Pharmaceutical Inc.
0.66%82.994.5%$116.36m
AAgilent Technologies, Inc.
0.72%44.851.6%$114.69m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. It focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.